Novavax, a vaccine development company headquartered in Gaithersburg, announced Thursday that it entered into a Memorandum of Understanding (MOU) with an international vaccine organization to provide more than 1 billion… Read More
Novavax, a vaccine development company headquartered in Gaithersburg, has initiated Phase 3 for its COVID-19 vaccine candidate. It is the fifth candidate to reach Phase 3 in the U.S., after… Read More
Gaithersburg biotechnology company Novavax announced Monday that it has reached an agreement in principle to give Canada up to 76 million doses of Novavax’s COVID-19 vaccine. In a statement the… Read More
A vaccine development company headquartered in Gaithersburg is starting clinical trials for a potential COVID-19 vaccine. Novavax will administer the trials for vaccine candidate NVX‑CoV2373 in two phases, a statement… Read More